Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q1 2015 Earnings Presentation
21 slides from Bactiguard Holding Ab's earnings presentation, May 12, 2015
Slide 1: Innovating for the healthcare needs of today and tomorrow
Innovating for the healthcare needs of today and tomorrow Q1 presentation 12 May 2015
Slide 2: Our Mission
Our Mission To prevent device related healthcare associated infections Reduce healthcare cost Reduce the use of antibiotics Prevent spread of multi-resistant bacteria Save lives 2
Slide 3: Healthcare associated infections – the most frequent adverse event in health care
Healthcare associated infections – the most frequent adverse event in health care Belgium 6.9% *Sweden 9% Germany 3.6% Canada 11.6% United Kingdom 9% Italy 6.7% Netherlands 7.2% USA 4.5% Turkey 12.5% France 4.4% Spain 8.1% Iran 8.8% Switzerland 8.8% Tanzania 15% Brazil 14% New Zeeland 12% Prevalence
Slide 4: The global health scare: Deaths attributable to AMR
The global health scare Deaths attributable to AMR Compared to other major causes of death ”Ten million people at risk if antimicrobial resistance is not tackled” ”The spread of AMR is expected to reduce global GDP by 2 – 3.5 percent” Source: Review on Antimicrobial Resistance (AMR), Tackling drug-r
Slide 5: Bactiguard Infection Protection
Targets the most common HAIs Bactiguard Infection Protection ...explaining the rationale behind the products in Occurrence of HAI US (all hospital types) the Bactiguard portfolio Other Urinary tract BIP Foley 17% 32% Surgical site 22% 14% 15% Blood stream BIP ETT Respiratory tract Medical devices, f
Slide 6: Initial reflections
Initial reflections Opportunities • Healthcare associated infections a major challenge across the world • Antibiotic resistance a growing threat to public health • There is an increasing need for prevention • Proven and effective technology, competent employees and satisfied customers Challenges and
Slide 7: First quarter performance
First quarter performance • Q1 weaker than in 2014 • Stable license business with C.R. Bard in the US • Lower deliveries of BIP portfolio, no territorial fees • Market expansion in Europe (Switzerland) • More Swedish hospitals start ordering our products and plan trials • Changed market strategy for
Slide 8: Highlights
Financial overview Highlights First quarter (Jan-Mar 2015) • Revenues of MSEK 28.8 (34.5), minus 16% compared to 2014 (no Territorial fees in Q1 2015, compared to 11.6 MSEK in 2014) • EBITDA of MSEK -26.8 (9.8), First quarter adjusted (Jan-Mar 2015) • Excluding provision for doubtful accounts receiv
Slide 9: Supplied products
Financial overview Supplied products • 4 650 BIP products supplied in Q1 2015 compared to approximately 16 000 during Q1 2014. • For the full year 2014, 79 000 BIP products were supplied 9
Slide 10: Revenue streams
Financial overview Revenue streams Three revenue streams in the income statement License BIP portfolio Bard license deal BIP Foley BIP ETT BIP CVC (sales since 1995) 1 2 3 License Territorial fee BIP revenue From a product perspective Bactiguard has two lines of business; Licenses and the BIP portfo
Slide 11: Income distribution
Financial overview Income distribution Jan-Mar Jan-Mar Full year MSEK 2015 2014 2014 License revenues 26,8 22,5 89,8 Territorial fees - 11,6 17,1 Sales of BIP products 0,1 0,1 2,2 Other revenue 1,9 0,3 9,8 Total Revenues 28,8 34,5 118,9 11
Slide 12: Key figures
Financial overview Key figures Jan-Mar Jan-Mar Full year Key figures • EBITDA (Q1) MSEK -26.8 2015 2014 2014 Revenues, SEKm 28,8 34,5 118,9 • Adjusted EBITDA, MSEK 2.0, EBITDA*, SEKm -26,8 9,8 13,3 7% margin EBITDA margin*, % -93% 29% 11% Operating profit, SEKm -34,9 2,4 -19,8 Net profit for the per
Slide 13: Financial flexibility and strength
Financial overview Financial flexibility and strength Q2 -14 Share issue of MSEK 20 in April Set off issue of MSEK 222.5 in June Share issue of MSEK 240 in connection with IPO Q3 -14 • Repurchase of bonds, nominal value MSEK 18.5 Q4 -14 • Repurchase of bonds, nominal value MSEK 20.5 Q1 -15 • R
Slide 14: Initial reflections
Initial reflections Opportunities • Healthcare associated infections a major challenge across the world • Antibiotic resistance a growing threat to public health • There is an increasing need for prevention • Proven and effective technology, competent employees and satisfied customers Challenges and
Slide 15: Focus sales efforts where we currently have market access
Focus sales efforts where we currently have market access, while creating additional access for the future 15
Slide 16: Focusing sales and marketing efforts on hospital departments and patient groups
Focusing sales and marketing efforts on hospital departments and patient groups with largest need for our products Share of # of patients catheter Patient group using Foley days Critically ill 74% 7 Stroke / CVA 44% 19 Dementia 25% 25 Prostate cancer 27% 13 Bladder cancer 21% 13 BPH/TURP 23% 17 Spin
Slide 17: Health economic value creation of Bactiguard product modeled per patient group
Health economic value creation of Bactiguard product modeled per prioritized patient group Economic Savings per patient due to reduced urinary tract Premium price spent per value infection rate from using Bactiguard patient to use Bactiguard 0 1 2 3 4 5 Health care economics approach EV = Cost of tr
Slide 18: Expand business and reduce complexity
Expand business and reduce complexity • Strengthen clinical evidence by conducting specific complementary studies • Using Lean methodologies, implement standardized processes and reduce complexity throughout the company • Finalize the transfer of production and headquarters an important aspect of th
Slide 19: The start up of the production is ongoing
The start up of the production is ongoing Production HQ transfer CE audit start December 2014 May 2015 June July August September BIP CVC BIP ETT validation validation, inventory transfer
Slide 20: Investing in Bactiguard is investing in the future
Investing in Bactiguard is investing in the future • Healthcare associated infections and antibiotic resistance - two of the greatest challenges of our time • Prevention is key - Bactiguard has efficient, safe and well proven solutions • We will concentrate efforts and resources on fewer markets • S
Slide 21: For more information
For more information Please visit our website: www.bactiguard.com For questions and additional information, please contact: Niels Christiansen, CEO: +46 8 440 58 78 niels.christiansen@bactiguard.se Fredrik Järrsten, CFO: +46 725 500 089 fredrik.jarrsten@bactiguard.se Cecilia Edström, Acting Director